Alyssin and Iberin in Cruciferous Vegetables Exert Anticancer Activity in HepG2 by Increasing Intracellular Reactive Oxygen Species and Tubulin Depolymerization
10.4062/biomolther.2019.027
- Author:
Piman POCASAP
1
;
Natthida WEERAPREEYAKUL
;
Kanjana THUMANU
Author Information
1. Research and Development in Pharmaceuticals Program, Graduate School, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.
- Publication Type:Original Article
- Keywords:
Isothiocyanates;
Iberin;
Alyssin;
Reactive oxygen species;
Tubulin depolymerization;
HepG2
- MeSH:
Apoptosis;
Carcinoma, Hepatocellular;
Cell Death;
DNA;
In Vitro Techniques;
Isothiocyanates;
Liver Neoplasms;
Necrosis;
Polymerization;
Polymers;
Reactive Oxygen Species;
Tubulin;
Vegetables
- From:Biomolecules & Therapeutics
2019;27(6):540-552
- CountryRepublic of Korea
- Language:English
-
Abstract:
To determine the chemopreventive potential of alyssin and iberin, the in vitro anticancer activities and molecular targets of isothiocyanates (ITCs) were measured and compared to sulforaphane in hepatocellular carcinoma cell HepG2. The SR-FTIR spectra observed a similar pattern vis-à-vis the biomolecular alteration amongst the ITCs-treated cells suggesting a similar mode of action. All of the ITCs in this study cause cancer cell death through both apoptosis and necrosis in concentration dependent manner (20–80 μM). We found no interactions of any of the ITCs studied with DNA. Notwithstanding, all of the ITCs studied increased intracellular reactive oxygen species (ROS) and suppressed tubulin polymerization, which led to cell-cycle arrest in the S and G₂/M phase. Alyssin possessed the most potent anticancer ability; possibly due to its ability to increase intracellular ROS rather than tubulin depolymerization. Nevertheless, the structural influence of alkyl chain length on anticancer capabilities of ITCs remains inconclusive. The results of this study indicate an optional, potent ITC (viz., alyssin) because of its underlying mechanisms against hepatic cancer. As a consequence, further selection and development of effective chemotherapeutic ITCs is recommended.
